278 related articles for article (PubMed ID: 33526787)
1. Mesenchymal stem cell-derived interleukin-28 drives the selection of apoptosis resistant bone metastatic prostate cancer.
McGuire JJ; Frieling JS; Lo CH; Li T; Muhammad A; Lawrence HR; Lawrence NJ; Cook LM; Lynch CC
Nat Commun; 2021 Feb; 12(1):723. PubMed ID: 33526787
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-6: a bone marrow stromal cell paracrine signal that induces neuroendocrine differentiation and modulates autophagy in bone metastatic PCa cells.
Delk NA; Farach-Carson MC
Autophagy; 2012 Apr; 8(4):650-63. PubMed ID: 22441019
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of STAT3 prevents bone metastatic progression of prostate cancer in vivo.
Thulin MH; Määttä J; Linder A; Sterbova S; Ohlsson C; Damber JE; Widmark A; Persson E
Prostate; 2021 Jun; 81(8):452-462. PubMed ID: 33822400
[TBL] [Abstract][Full Text] [Related]
4. Mouse bone marrow-derived mesenchymal stem cells induce macrophage M2 polarization through the nuclear factor-κB and signal transducer and activator of transcription 3 pathways.
Gao S; Mao F; Zhang B; Zhang L; Zhang X; Wang M; Yan Y; Yang T; Zhang J; Zhu W; Qian H; Xu W
Exp Biol Med (Maywood); 2014 Mar; 239(3):366-75. PubMed ID: 24500984
[TBL] [Abstract][Full Text] [Related]
5. Osteoblast-derived sphingosine 1-phosphate to induce proliferation and confer resistance to therapeutics to bone metastasis-derived prostate cancer cells.
Brizuela L; Martin C; Jeannot P; Ader I; Gstalder C; Andrieu G; Bocquet M; Laffosse JM; Gomez-Brouchet A; Malavaud B; Sabbadini RA; Cuvillier O
Mol Oncol; 2014 Oct; 8(7):1181-95. PubMed ID: 24768038
[TBL] [Abstract][Full Text] [Related]
6. Loss of let-7 microRNA upregulates IL-6 in bone marrow-derived mesenchymal stem cells triggering a reactive stromal response to prostate cancer.
Sung SY; Liao CH; Wu HP; Hsiao WC; Wu IH; Jinpu ; Yu ; Lin SH; Hsieh CL
PLoS One; 2013; 8(8):e71637. PubMed ID: 23977098
[TBL] [Abstract][Full Text] [Related]
7. Gefitinib inhibits the cross-talk between mesenchymal stem cells and prostate cancer cells leading to tumor cell proliferation and inhibition of docetaxel activity.
Borghese C; Cattaruzza L; Pivetta E; Normanno N; De Luca A; Mazzucato M; Celegato M; Colombatti A; Aldinucci D
J Cell Biochem; 2013 May; 114(5):1135-44. PubMed ID: 23192362
[TBL] [Abstract][Full Text] [Related]
8. Acetyl-11-keto-β-boswellic acid suppresses docetaxel-resistant prostate cancer cells in vitro and in vivo by blocking Akt and Stat3 signaling, thus suppressing chemoresistant stem cell-like properties.
Liu YQ; Wang SK; Xu QQ; Yuan HQ; Guo YX; Wang Q; Kong F; Lin ZM; Sun DQ; Wang RM; Lou HX
Acta Pharmacol Sin; 2019 May; 40(5):689-698. PubMed ID: 30171201
[TBL] [Abstract][Full Text] [Related]
9. Cancer-bone microenvironmental interactions promotes STAT3 signaling.
Henderson VM; Hawsawi O; Burton LJ; Campbell T; Trice K; Dougan J; Howard SM; Odero-Marah VA
Mol Carcinog; 2019 Aug; 58(8):1349-1361. PubMed ID: 31045290
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of skeletal growth of human prostate cancer by the combination of docetaxel and BKM1644: an aminobisphosphonate derivative.
Zhang S; Gera L; Mamouni K; Li X; Chen Z; Kucuk O; Wu D
Oncotarget; 2016 May; 7(19):27489-98. PubMed ID: 27050371
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-6/interleukin-6 receptor complex promotes osteogenic differentiation of bone marrow-derived mesenchymal stem cells.
Xie Z; Tang S; Ye G; Wang P; Li J; Liu W; Li M; Wang S; Wu X; Cen S; Zheng G; Ma M; Wu Y; Shen H
Stem Cell Res Ther; 2018 Jan; 9(1):13. PubMed ID: 29357923
[TBL] [Abstract][Full Text] [Related]
12. Bone-metastatic prostate carcinoma favors mesenchymal stem cell differentiation toward osteoblasts and reduces their osteoclastogenic potential.
Fritz V; Brondello JM; Gordeladze JO; Reseland JE; Bony C; Yssel H; Noël D; Jorgensen C
J Cell Biochem; 2011 Nov; 112(11):3234-45. PubMed ID: 22009438
[TBL] [Abstract][Full Text] [Related]
13. Betaglycan drives the mesenchymal stromal cell osteogenic program and prostate cancer-induced osteogenesis.
Cook LM; Frieling JS; Nerlakanti N; McGuire JJ; Stewart PA; Burger KL; Cleveland JL; Lynch CC
Oncogene; 2019 Oct; 38(44):6959-6969. PubMed ID: 31409900
[TBL] [Abstract][Full Text] [Related]
14. p62/SQSTM1 is required for cell survival of apoptosis-resistant bone metastatic prostate cancer cell lines.
Chang MA; Morgado M; Warren CR; Hinton CV; Farach-Carson MC; Delk NA
Prostate; 2014 Feb; 74(2):149-63. PubMed ID: 24122957
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-6 maintains bone marrow-derived mesenchymal stem cell stemness by an ERK1/2-dependent mechanism.
Pricola KL; Kuhn NZ; Haleem-Smith H; Song Y; Tuan RS
J Cell Biochem; 2009 Oct; 108(3):577-88. PubMed ID: 19650110
[TBL] [Abstract][Full Text] [Related]
16. STAT3 activation by IL-6 from mesenchymal stem cells promotes the proliferation and metastasis of osteosarcoma.
Tu B; Du L; Fan QM; Tang Z; Tang TT
Cancer Lett; 2012 Dec; 325(1):80-8. PubMed ID: 22743617
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of STAT3 signaling targets both tumor-initiating and differentiated cell populations in prostate cancer.
Han Z; Wang X; Ma L; Chen L; Xiao M; Huang L; Cao Y; Bai J; Ma D; Zhou J; Hong Z
Oncotarget; 2014 Sep; 5(18):8416-28. PubMed ID: 25261365
[TBL] [Abstract][Full Text] [Related]
18. Mesenchymal stem cells recruited by castration-induced inflammation activation accelerate prostate cancer hormone resistance via chemokine ligand 5 secretion.
Yu Y; Zhang Q; Ma C; Yang X; Lin R; Zhang H; Liu Y; Han Z; Cheng J
Stem Cell Res Ther; 2018 Sep; 9(1):242. PubMed ID: 30257726
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells.
Liu C; Zhu Y; Lou W; Cui Y; Evans CP; Gao AC
Prostate; 2014 Feb; 74(2):201-9. PubMed ID: 24307657
[TBL] [Abstract][Full Text] [Related]
20. Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes.
Izumi K; Mizokami A; Li YQ; Narimoto K; Sugimoto K; Kadono Y; Kitagawa Y; Konaka H; Koh E; Keller ET; Namiki M
Prostate; 2009 Aug; 69(11):1222-34. PubMed ID: 19434660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
